Viewmind

About Viewmind

ViewMind operates in the digital health sector, providing solutions for the precision diagnosis and management of neurocognitive disorders. The company’s core technology is centered on ocular digital phenotyping, which analyzes subtle, reproducible alterations in eye movements to assess cognitive health. This technology is rooted in over two decades of scientific research led by Chief Science Officer and co-founder, Dr. Gerardo Fernandez, which has resulted in 79 peer-reviewed publications. The company was officially formed in 2018 by co-founders including Mark Edwards, who serves as CEO, and Matias Shulz, to commercialize this research. Mark Edwards brings over 25 years of experience in the technology industry, having led and founded multiple companies in software, AI, and mobile sectors.

ViewMind's service involves a non-invasive assessment, typically lasting between 13 to 20 minutes, where a patient wears a virtual reality (VR) headset equipped with high-precision eye-tracking sensors. The system, which partners with HP for hardware, captures around 100,000 data points by tracking eye movements in response to a series of visual stimuli. This data is then uploaded to the cloud and analyzed by proprietary AI algorithms to generate a detailed report for physicians, offering insights into various cognitive domains and their corresponding brain regions. This process can identify minor cognitive changes long before clinical symptoms appear, with studies showing the ability to detect alterations in Familial Alzheimer's Disease patients up to 20 years before symptom onset and with sensitivity and specificity in the high 90th percentile.

The company's business model targets two primary client groups: pharmaceutical companies and healthcare institutions. For the pharmaceutical industry, ViewMind's technology aids in clinical trials by improving patient screening, stratification, and cohort harmonization, which can reduce screen failure rates by over 50% and more accurately measure a drug's impact on cognition. For healthcare providers, including neurology offices and preventative care clinics, the platform serves as a diagnostic tool for the early detection and ongoing monitoring of conditions such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, and neurological Long COVID. The assessment is designed to be independent of a patient's language, culture, or education level, making it a globally scalable solution. Having secured regulatory approval in Europe, Latin America, and parts of Asia, ViewMind is also undergoing the FDA approval process for the U.S. market.